title: Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis.
abstract: OBJECTIVE
  Usually it is not possible to study the initial systemic response in patients with acute pancreatitis in the first hours after onset of the disease. We used postendoscopic retrograde pancreatography (ERP) pancreatitis as a model to study cytokine and anticytokine release in the early phase of human acute pancreatitis.
  
  
  METHODS
  Post-ERP pancreatitis was defined as a threefold increase in serum amylase and at least two of the following clinical symptoms: abdominal pain, nausea, vomiting or peritonism 24 h after ERP. Serum levels of pro-inflammatory cytokines interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor alpha (TNF), as well as endogenous antagonistic mediators of the systemic inflammatory response such as soluble tumour necrosis factor alpha receptors p55 (TNFR p55) and p75 (TNFR p75), and IL-1-receptor antagonist (IL-1-RA) and interleukin-2-receptor (IL-2R) as indicators of lymphocyte activation were measured before and 0, 1, 4, 12, 24 and 48 h after ERP. In nine patients with acute post-ERP pancreatitis, these parameters were monitored daily until C-reactive protein (CRP) was within normal ranges and were compared to patients without pancreatitis after ERP.
  
  
  RESULTS
  IL-1beta was not detectable in five patients with and four patients without post-ERP pancreatitis. The values of the remaining patients in both groups were lower than 3.9 pg/ml. IL-8 and IL-1-RA serum concentrations peaked 12 h after ERP (132.9 and 3245.0 pg/ml respectively) compared to patients without post-ERP pancreatitis (25.8 and 389.9 pg/ml respectively). The IL-6 concentration increased to 81.6 pg/ml (8.0 pg/ml in control patients) 24 h after ERP, while the peak values for CRP were measured 72 h after ERP (164.0 versus 7.7 mg/l). IL-2R content was maximally elevated 144 h after ERP (688.8 versus 255.9 U/ml), while concentrations of TNF and its receptors showed no significant change over time.
  
  
  CONCLUSIONS
  The initial response of the cytokine network to damage of the human pancreas leading to acute pancreatitis includes the release of IL-8 and the IL-1 antagonist IL-1-RA, while IL-1beta is not found in the systemic circulation. The TNF system does not seem to be involved as indicated by the lack of detectable changes in TNF and the soluble TNFR p55 and p75 serum concentrations. Lymphocyte activation as indicated by elevated IL-2R levels occurred days after the initial trauma. Even mild post-ERP pancreatitis leads to significant systemic release of cytokines and their biological counterparts.
authors.affiliation: Department of Internal Medicine I, University of Regensburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Messmann
authors.forename: W
authors.initials: W
authors.lastname: Vogt
authors.forename: W
authors.initials: W
authors.lastname: Falk
authors.forename: D
authors.initials: D
authors.lastname: Vogl
authors.forename: H
authors.initials: H
authors.lastname: Zirngibl
authors.forename: H G
authors.initials: HG
authors.lastname: Leser
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D000208:Acute Disease; D015703:Antigens, CD / Q000032:analysis; D002760:Cholangiopancreatography, Endoscopic Retrograde; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007378:Interleukins / Q000037:antagonists & inhibitors / Q000097:blood*; D010195:Pancreatitis / Q000097:blood*; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis*; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
chemical_list: D015703:Antigens, CD; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D016209:Interleukin-8; D007378:Interleukins; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha